At Euronext Paris, the Abivax share gains significantly today. The share price of the biotech company is currently up around 37 percent at EUR 31.65, the daily high was even recorded at EUR 39 after yesterday’s closing price of EUR 23.10. The price jump was triggered by news from the French company about its ongoing phase 2b / 3 clinical trial with the active ingredient ABX464, which is being tested in the treatment of older and high-risk COVID-19 patients.
Abivax reports that the project has now been declared a national priority research project by the French government. “National-priority research projects will have priority in enrolling patients in clinical trials through an accelerated review and approval process from French regulatory agencies,” said the company, commenting on the rationale behind the decision, which should accelerate development of ABX464. Abivax is expecting the results of the approval-relevant study for the second quarter of next year.
“Abivax is conducting this clinical trial with great international commitment and at the same time is accelerating the production expansion of ABX464 for possible commercialization in 2021,” said Philippe Pouletty, Chairman of the Board of Abivax. In addition, the biotech company assumes that there are no effects of possible virus mutations on the mechanism of action of ABX464.
Livestream on December 14th, 2020 from 6 p.m .:
With Hans-Werner Sinn, former President of the Ifo Institute: Corona and the miraculous increase in money in Europe
– Here is the stream! –